Results 61 to 70 of about 2,303 (187)

Palivizumab for Donor‐Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report

Respirology Case Reports, Volume 14, Issue 8, August 2026.
We describe the use of off‐label palivizumab in an early post‐operative bilateral lung transplant recipient with probable donor‐derived RSV who developed persistent severe LRTI and respiratory failure. RSV PCR Ct fell and remained low from day 0 to day 42 despite conventional therapy until palivizumab was administered on day 44, following which we ...
Rosemary Meharry, Cassandra Vale, John Mackintosh   +2 more
wiley   +1 more source

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +1 more source

Results From the Third and Fourth WHO External Quality Assessments for the Molecular Detection of Respiratory Syncytial Virus

Influenza and Other Respiratory Viruses, Volume 20, Issue 8, August 2026.
ABSTRACT Background In 2016, the World Health Organization (WHO) initiated the global RSV surveillance programme, which aimed to strengthen laboratory diagnostic capacity and evaluate molecular detection test performance. External quality assessments (EQAs) are conducted regularly as part of this programme to ensure ongoing laboratory proficiency.
Fernando do Couto Motta, Obadiah Kenji, Ian Barr, Shabana Bi, Anne von Gottberg, Jean‐Michel Heraud, Siddhi Hirve, Sanjiv Rughooputh, Nicole Wolter, Maria Zambon, Thomas C. Williams, Wenqing Zhang   +11 more
wiley   +1 more source

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality—United States, 2014–2024

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations among infants and older adults in the United States. Determining RSV seasonality, which varies geographically, is essential to the timely administration of prevention products.
Sophia Chkonia, Sarah Hamid, Erica Billig Rose, Amber Winn, Erin Anderson, Benjamin J. Silk   +5 more
wiley   +1 more source

Correlations and Timeliness of Respiratory Syncytial Virus Surveillance Indicators—United States, 2018–2024

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations in young children and older adults in the United States. Monitoring seasonal RSV activity through national surveillance systems and understanding the relationships among RSV surveillance indicators can help ensure timely administration of prevention products and ...
Erin L. Anderson, Erica Billig Rose, Amber Winn, Sophia Chkonia, Heidi Moline, Ariana Toepfer, Monica E. Patton, Christopher A. Taylor, Aaron Kite‐Powell, Stephanie Dietz, Michael Sheppard, Jourdan DeVies, Benjamin J. Silk   +12 more
wiley   +1 more source

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease, and the standard prevention strategy in Japan is limited to high-risk infants.
Shinichi Noto, Alexia Kieffer, Samira Soudani, Takeshi Arashiro, Chiho Tadera, Sebastien Eymere, Tobiasz Lemański, Xinyu Wang   +7 more
doaj   +1 more source

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

Frontiers in Immunology
BackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang, Xiaopeng Wang, Xiaopeng Wang, Li Kong, Li Kong, Li Kong, Xueou Liu, Panpan Wu, Panpan Wu, Panpan Wu, Lulu Zhang, Lulu Zhang, Lulu Zhang, Fangrui Ding, Fangrui Ding, Fangrui Ding   +15 more
doaj   +1 more source